Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

Next Previous
X
Search
Trial Profile

A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iberdomide (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation

    • Most Recent Events

    • 15 Nov 2023 Results (n=276) assessing to identify the profile of gene expression abnormalities in systemic lupus erythematosus patients responsive to iberdomide and the impact of the agent on gene expression abnormalities, presented at the ACR Convergence 2023.
    • 03 Jun 2023 Blood samples from 276 female SLE patients from this study were used to identify subsets of SLE patients responsive to iberdomide more effectively by analyzing baseline gene expression profiles, presented at the 24th Annual Congress of the European League Against Rheumatism.
    • 27 Apr 2022 Results assessing biological impact of iberdomide in patients with active systemic lupus erythematosus, published in the Annals of the Rheumatic Diseases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top